Crispr Therapeutics AG Stock Surges on Strategic Moves and Promising Clinical Updates

Crispr Therapeutics AG's stock has risen 10.96% due to notable investment moves from Cathie Wood's ARK Invest and a reaffirmation of a Buy rating from Needham. Analysts remain positive, highlighting the company's strategic positioning, robust treatment pipeline, and promising clinical study updates in the genetic editing landscape.

Crispr Therapeutics AG (CRSP) has seen its stock price rise by 10.96% as of July 2, 2025, driven by notable investment moves from Cathie Wood’s ARK Invest and a reaffirmation of a Buy rating from Needham. These developments have further solidified the company’s strategic positioning and robust pipeline in the genetic editing landscape.

ARK Invest, managed by Cathie Wood, has been a significant player in the gene-editing sector. On July 8, 2025, ARKK ETF purchased 102,806 shares of CRISPR Therapeutics AG, valued at approximately $5.26 million [1]. This move reflects ARK’s confidence in CRISPR’s pioneering gene-editing platform and its potential for blockbuster therapies. Concurrently, ARKK ETF sold 20,813 shares of Roku Inc (NASDAQ:ROKU) and 62,307 shares of 908 Devices Inc (NASDAQ:MASS), indicating a strategic shift away from these stocks [1].

Needham & Company has reaffirmed its BUY rating for CRISPR Therapeutics AG, citing a fair value estimate of $106 per share, nearly double the recent closing price of $54.82 [2]. The firm highlights CRISPR’s strong cash position, diversified pipeline, and the commercial rollout of its flagship therapy Casgevy, which targets sickle cell disease and transfusion-dependent beta-thalassemia. Casgevy has received regulatory approval in several key geographies and is priced competitively, undercutting BlueBird Bio’s Lyfgenia.

Analysts remain bullish on CRISPR Therapeutics AG, with 22 out of 22 analysts giving a Moderate Buy rating and an average price target of $67.94, representing a 19.61% upside from the last price [3]. Analysts like Gil Blum of TipRanks and Liisa Bayko of Evercore ISI are particularly optimistic, with price targets ranging from $81 to $99. They emphasize CRISPR’s strong strategic positioning, robust treatment pipeline, and promising clinical study updates.

Investors should continue to monitor CRISPR Therapeutics AG’s pipeline milestones, regulatory approvals, and updates on competitive dynamics. The company’s strong cash position and advancing pipeline provide a buffer against near-term volatility, while the stock’s deep discount to fair value offers asymmetric upside potential.

References:

[1] https://www.investing.com/news/company-news/cathie-woods-ark-buys-crsp-stock-sells-roku-and-mass-93CH-4127391

[2] https://topnews.in/crispr-therapeutics-ag-crsp-stock-undervalued-morningstar-recommends-buy-call-106-fair-value-2417749

[3] https://www.tipranks.com/stocks/crsp/forecast